Author:
Upadhyay Tarun K.,Sharma Akanksha,Fatima Nida,Singh Amit,Muttil Pavan,Sharma Rolee
Reference66 articles.
1. Ahmad, S. (2010). Pathogenesis, immunology, and diagnosis of latent Mycobacterium tuberculosis infection. Clinical & Developmental Immunology, 2011, 814943.
2. Ahmad, Z., Sharma, S., & Khuller, G. K. (2007). Chemotherapeutic evaluation of alginate nanoparticle-encapsulated azole antifungal and antitubercular drugs against murine tuberculosis. Nanomedicine: Nanotechnology, Biology and Medicine, 3(3), 239–243.
3. Ahmad, Z., Pandey, R., Sharma, S., & Khuller, G. K. (2008). Novel chemotherapy for tuberculosis: Chemotherapeutic potential of econazole-and moxifloxacin-loaded PLG nanoparticles. International Journal of Antimicrobial Agents, 31, 142–146.
4. Ahmad, Z., Maqbool, M., & Raja, A. F. (2011). Nanomedicine for tuberculosis: Insights from animal models. International Journal of Nano Dimension, 2(1), 67–84.
5. Ahmed, M. M., Velayati, A. A., & Mohammed, S. H. (2016). Epidemiology of multidrug-resistant, extensively drug resistant, and totally drug resistant tuberculosis in Middle East countries. International Journal of Mycobacteriology, 5(3), 249–256.